Bear market blues: Infosys tumbles 22% from peak, Wiping out Rs 6,800 crore from Narayana Murthy’s family wealth

Infosys, once a darling of the IT sector, has hit a rough patch. With a year-to-date (YTD) decline of 16%, the IT giant has entered bear market territory. In just the last five days, its share price of Infosys has tumbled nearly 7%, leaving investors anxious and wiping out significant wealth. Among those hit the hardest is none other than Infosys co-founder Narayana Murthy and his family, whose stake in the company has reportedly lost a staggering approx. Rs 6,875 crore in value.

The numbers behind the wealth erosion

On March 12, Infosys share price plunged over 5%, extending a two-day slide of over 8%. Murthy’s family collectively holds a 4.02% stake in Infosys, which, as of March 12, is valued at Rs 26,287 crore. This marks a drop from its approx. Rs 33,163 crore valuation just three months ago.

Narayana Murthy personally owns a 0.40% stake, now worth around Rs 3,299.79 crore, a decline of Rs 684 crore.

Sudha Murty, his wife, holds 0.92%, with her stake now valued at approx. Rs 7,600.41 crore, a loss of around Rs 1,573.54 crore.

ALSO READTCS Vs Infosys: Morgan Stanley’s surprising pick and why

Rohan Murty, their son and the largest stakeholder in the family with 1.62%, saw his holding shrink by around Rs 2,771 crore, bringing the value down to about Rs 13,378.5 crore.

Akshata Murty, Narayana Murthy’s daughter and the wife of former UK Prime Minister Rishi Sunak, owns 1.04%, with her stake now worth Rs 8,591 crore, an approx. Rs 1,779 crore decline.

Ekagrah Rohan Murty, Murthy’s grandson, holds a minor 0.04% stake, which has also taken a hit.

Adding to the woes, global brokerage downgrades and concerns over weakening IT spending in the US, also had a significant impact on Infosys key market.

Infosys under pressure: What’s driving the sell-off?

The sell-off in Infosys shares is not happening in isolation. The broader IT sector has been under pressure, with the Nifty IT index as well facing the pressure amid global concerns. Infosys, along with peers Wipro and HCL Tech, has led the decline.

Brokerage firm Morgan Stanley recently downgraded the stock to ‘equal-weight’ and slashed its target price from Rs 2,150 to Rs 1,740.

 » Read More

Related Articles

Zydus Lifesciences – Will it succeed in aggressively moving up the value chain?

By Amriteshwar Mathur Zydus Lifesciences is attempting to move up the value chain in the global pharma industry with its expanding focus on the medical technology segment. As part of the above strategy, Zydus Lifesciences has made a foray in the higher margin orthopedic products segment with an acquisition of 85.6% stake in France-based Amplitude

Two chemical stocks indicating strength and reversal

By Kiran Jani The chemical sector, which has been on a downward trend for the past five months is finally showing signs of a recovery. With prices stabilising and the broader market improving, some stocks are showing potential for a turnaround. HEG and Graphite have formed potential reversal patterns, indicating possible opportunities for traders and

Three auto stocks potentially at bargain buying point

The market has been in a corrective phase for the seventh consecutive month, with many stocks taking a significant dip of 20-40%. After a period of stellar returns between 2020 and 2024, investor expectations were sky-high, but the recent downturn has led to many losing interest in the markets. While these dips have been challenging

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Zydus Lifesciences – Will it succeed in aggressively moving up the value chain?

By Amriteshwar Mathur Zydus Lifesciences is attempting to move up the value chain in the global pharma industry with its expanding focus on the medical technology segment. As part of the above strategy, Zydus Lifesciences has made a foray in the higher margin orthopedic products segment with an acquisition of 85.6% stake in France-based Amplitude

Two chemical stocks indicating strength and reversal

By Kiran Jani The chemical sector, which has been on a downward trend for the past five months is finally showing signs of a recovery. With prices stabilising and the broader market improving, some stocks are showing potential for a turnaround. HEG and Graphite have formed potential reversal patterns, indicating possible opportunities for traders and

Three auto stocks potentially at bargain buying point

The market has been in a corrective phase for the seventh consecutive month, with many stocks taking a significant dip of 20-40%. After a period of stellar returns between 2020 and 2024, investor expectations were sky-high, but the recent downturn has led to many losing interest in the markets. While these dips have been challenging

Is your FD really safe? Know insurance coverage for your deposits with IndusInd and other banks

IndusInd Bank is in the news this week as its stock crashed to a 52-week low (on March 11, 2025) due to an accounting error linked to forex derivative transactions. However, the stock recovered slightly the next day. This financial mess, which might not directly harm ordinary depositors, has once again drawn attention to bank

Baba Ramdev’s Patanjali Ayurved enters insurance sector with majority stake in Magma General Insurance

Baba Ramdev-owned Patanjali Ayurved has expanded its business footprint by acquiring a majority stake in Magma General Insurance. This strategic move marks Patanjali’s entry into the competitive general insurance sector, further diversifying its portfolio beyond its established Ayurvedic, wellness, and consumer goods offerings, reports CNBC TV18. Following the acquisition, Patanjali Ayurved will become the promoter